Immunocellular Therapeutics Ltd., of Los Angeles, issued a letter to shareholders about its ICT-107 program in newly diagnosed glioblastoma (GBM), indicating the company is continuing to analyze data from the trial and consulted with neuro-oncology experts to determine its next development and regulatory activities for ICT-107.